반응식
Cc1csc(N)n1.O=C1OCCCN1c1cccc(Br)n1>CC1(C)c2cccc(P(c3ccccc3)c3ccccc3)c2Oc2c(P(c3ccccc3)c3ccccc3)cccc21.Cc1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C([O-])[O-].[Cs+].[Cs+].[Pd]>Cc1csc(Nc2cccc(N3CCCOC3=O)n2)n1참가 물질
반응물 2
생성물 1
시약·촉매·용매 4
반응 조건
- 온도
- 120 °C
실험 절차
**_September 21 2015_** 4-methylthiazol-2-amine (85 mg, 0.74 mmol), 3-(6-bromopyridin-2-yl)-1,3-oxazinan-2-one (191 mg, 0.74 mmol), 3-(6-bromopyridin-2-yl)-1,3-oxazinan-2-one (191 mg, 0.74 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (43.1 mg, 0.07 mmol) and cesium carbonate (291 mg, 0.89 mmol) in toluene (5 mL) were microwaved at 120 °C under N2 for one hour. LCMS showed no precursors and 51% of the desired mass MH+291 @ 0.86 min on a 2-min basic run. The reaction mixture was diluted with EtOAc, washed with water, filtered, and evaporated to give a brown solid as the crude product. The crude product was added to a Biotage column, and was eluted with 15-100%EtOAc in Heptane. Collected fractions. **_September 22 2015_** Based on TLC and LCMS, the product fractions were combined, and evpoarated to give an yellow-brown solid (94 mg). Based on LCMS, it was only 89% pure. Based on LCMS, it was 96% pure; based on NMR, it was > 95% pure.
출처 및 근거
- ORD 기록
- ord-db902466b4d9464996daff204ba92575
- 출처 데이터셋
- 750 AstraZeneca ELN dataset
- 원본 링크
- 출처 보기
연결된 노트
불러오는 중…